Insulin-like growth factor 1 receptor expression in advanced non-small-cell lung cancer and its impact on overall survival
References
- International Agency for Research on Cancer. World health Organization. GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 20012. Lung cancer fact sheet. [Citated 2016 Jun 15]. Available at http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx?cancer=lung.
- Morgensztern D, Ng SH, Gao F, Govindan R. Trends in stage distribution for patients with non-small cell lung cancer: A National Cancer Database survey. J Thorac Oncol 2010; 5: 29-33. 10.1097/JTO.0b013e3181c5920c
- Debevec L, Jerič T, Kovač V, Bitenc M, Sok M. Is there any progress in routine management of lung cancer patients? A comparative analysis of an institution in 1996 and 2006. Radiol Oncol 2009; 43: 47-53. 10.2478/v10019-009-0008-x
- Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Altekruse SF, et al.SEER cancer statistics review, 1975-2013. Bethesda: National Cancer Institute. [Citated 2016 Sept 04]. Available at http://seer.cancer.gov/csr/1975_2013/
- Sechler M, Cizmic AD, Avasarala S, Van Scoyk M, Brzezinski C, Kelley N, et al. Non-small-cell lung cancer: molecular targeted therapy and personalized medicine – drug resistance, mechanisms, and strategies. Pharmgenomics Pers Med 2013; 6: 25-36. 10.2147/PGPM.S26058
- Zwitter M, Stanic K, Rajer M, Kern I, Vrankar M, Edelbaher N, Kovac V. Intercalated chemotherapy and erlotinib for advanced NSCLC: high proportion of complete remissions and prolonged progression-free survival among patients with EGFR activating mutations. Radiol Oncol 2014; 48: 361-8. 10.2478/raon-2014-0038
- Wang J, Wang B, Chu H, Yao Y. Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations. Onco Targets Ther 2016; 9: 3711-26. 10.2147/OTT.S106399
- Ward CW, Garrett TP, McKern NM, Lou M, Cosgrove LJ, Sparrow LG, et al. The three dimensional structure of the type I insulin-like growth factor receptor. Mol Pathol 2001; 54: 125-32.
- Blakesley VA, Stannard BS, Kalebic T, Helman LJ, LeRoith D. Role of the IGF-I receptor in mutagenesis and tumor promotion. J Endocrinol 1997; 152: 339-44.
- Eckstein N, Servan K, Hildebrandt B, Politz A, von Jonquières G, Wolf-Kümmeth S, et al. Hyperactivation of the insulin-like growth factor receptor I signalling pathway is an essential event for cisplatin resistance of ovarian cancer cells. Cancer Res 2009; 69: 2996-3003. 10.1158/0008-5472.CAN-08-3153
- Huang F, Xu LA, Khambata-Ford S. Correlation between gene expression of IGF-1R pathway markers and cetuximab benefit in metastatic colorectal cancer. Clin Cancer Res 2012; 18: 1156-66. 10.1158/1078-0432.CCR-11-1135
- Yuen JS, Akkaya E, Wang Y, Takiguchi M, Peak S, Sullivan M, et al. Validation of the type 1 insulin-like growth factor receptor as a therapeutic target in renal cancer. Mol Cancer Ther 2009; 8: 1448-59. 10.1158/1535-7163.MCT-09-0101
- Suda K, Mizuuchi H, Sato K, Takemoto T, Iwasaki T, Mitsudomi T. The insulinlike growth factor 1 receptor causes acquired resistance to erlotinib in lung cancer cells with the wild-type epidermal growth factor receptor. Int J Cancer 2014; 135: 1002-6. 10.1002/ijc.28737
- Yeo CD, Park KH, Park CK, Lee SH, Kim SJ, Yoon HK, et al. Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in nonsmall cell lung cancer patients harboring activating EGFR mutations. Lung Cancer 2015; 87: 311-7. 10.1016/j.lungcan.2015.01.004
- Lovly CM, McDonald NT, Chen H, Ortiz-Cuaran S, Heukamp LC, Yan Y, et al. Rationale for co-targeting IGF1R and ALK in ALK fusion-positive lung cancer. Nat Med 2014; 20: 1027-34. 10.1038/nm.3667
- Beckwith H, Yee D. Minireview: Were the IGF signaling inhibitors all bad? Mol Endocrinol 2015; 29: 1549-57. 10.1210/me.2015-1157.
- Yerushalmi R, Gelmon KA, Leung S, Gao D, Cheang M, Pollak M, et al. Insulinlike growth factor receptor (IGF-1R) in breast cancer subtypes. Breast Cancer Res Treat 2012; 132: 131-42. 10.1007/s10549-011-1529-8
- Mountzios G, Aivazi D, Kostopoulos I, Kourea HP, Kouvatseas G, Timotheadou E, et al. Differential expression of the insulin-like growth factor receptor among early breast cancer subtypes. PLoS One 2014; 9: e91407. 10.1371/journal.pone.0091407
- Bahhnassy A, Mohanad M, Shaarawy S, Ismail MF, El-Bastawisy A, Ashmawy AM, et al. Transforming growth factor-β, insulin-like growth factor I/insulin-like growth factor I receptor and vascular endothelial growth factor-A: prognostic and predictive markers in triple-negative and non-triple-negative breast cancer. Mol Med Rep 2015; 12: 851-64. 10.3892/mmr.2015.3560
- Mountzios G, Kostopoulos I, Kotoula V, Sfakianaki I, Fountzilas E, Markou K, et al. Insulin-like growth factor 1 receptor (IGF1R) expression and survival in operable squamous-cell laryngeal cancer. PLoS One 2013; 8: e54048. 10.1371/journal.pone.0054048
- Huang Y-F, Shen M-R, Hsu K-F, Cheng Y-M, Chou C-Y. Clinical implications of insulin-like growth factor 1 system in early-stage cervical cancer. Br J Cancer 2008; 99: 1096-102. 10.1038/sj.bjc.6604661
- Hirakawa T, Yashiro M, Murata A, Hirata K, Kimura K, Amano R, et al. IGF-1 receptor and IGF binding protein-3 might predict prognosis of patients with resectable pancreatic cancer. BMC Cancer. 2013; 13: 392. 10.1186/1471-2407-13-392
- Numata K, Oshima T, Sakamaki K, Yoshihara K, Aoyama T, Hayashi T, et al. Clinical significance of IGF1R gene expression in patients with Stage II/III gastric cancer who receive curative surgery and adjuvant chemotherapy with S-1. J Cancer Res Clin Oncol 2016; 142: 415-22. 10.1007/s00432-015-2039-6
- Sichani MM, Yazdi FS, Moghaddam NA, Chehrei A, Kabiri M, Naeimi A, et al. Prognostic value of insulin-like growth factor-I receptor expression in renal cell carcinoma. Saudi J Kidney Dis Transpl 2010; 21: 69-74.
- Gonzalez-Roibon N, Kim JJ, Faraj SF, Chaux A, Bezerra SM, Munari E, et al. Insulin-like growth factor-1 receptor overexpression is associated with outcome in invasive urothelialcarcinoma of urinary bladder: a retrospective study of patients treated using radical cystectomy. Urology 2014; 83: 1444. e1-6. 10.1016/j.urology.2014.01.028
- Cappuzzo F, Varella-Garcia M, Finocchiaro G, Skokan M, Gajapathy S, Carnaghi C, et al. Primary resistance to cetuximab therapy in EGFR FISHpositive colorectal cancer patients. Br J Cancer 2008; 99: 83-9. 10.1038/sj.bjc.6604439
- Takahari D, Yamada Y, Okita N, T, Honda T, Hirashima Y, Matsubara J, et al. Relationships of insulin-like growth factor-1 receptor and epidermal growth factor receptor expression to clinical outcomes in patients with colorectal cancer. Oncology 2009; 76: 42-8. 10.1159/000178164
- Joehlin-Price AS, Stephens JA, Zhang J, Backes FJ, Cohn DE, Suarez AA. Endometrial cancer insulin-like growth factor 1 receptor (IGF1R) expression increases with body mass index and is associated with pathologic extent and prognosis. Cancer Epidemiol Biomarkers Prev 2016; 25: 438-45. 10.1158/1055-9965.EPI-15-1145
- Peiró G, Lohse P, Mayr D, Diebold J. Insulin-like growth factor-I receptor and PTEN protein expression in endometrial carcinoma. Correlation with bax and bcl-2 expression, microsatellite instability status, and outcome. Am J Clin Pathol 2003; 120: 78-85. 10.1309/C1KA-H1PR-L1UB-W798
- Dziadziuszko R, Merrick DT, Witta SE, Mendoza AD, Szostakiewicz B, Szymanowska A, et al. Insulin-like growth factor receptor 1 (IGF1R) gene copy number is associated with survival in operable non-small-cell lung cancer: a comparison between IGF1R fluorescent in situ hybridization, protein expression, and mRNA expression. J Clin Oncol 2010; 28: 2174-80. 10.1200/JCO.2009.24.6611
- Lee CY, Jeon JH, Kim HJ, Shin DH, Roh TW, Ahn CM, et al. Clinical significance of insulin-like growth factor-1 receptor expression in stage I non-small-cell lung cancer: immunohistochemical analysis. Korean J Intern Med 2008; 23: 116-20. 10.3904/kjim.2008.23.3.116
- Gong Y, Yao E, Shen R, Goel A, Arcila M, Teruya-Feldstein J, et al. High expression levels of total IGF-1R and sensitivity of NSCLC cells in vitro to an anti-IGF-1R antibody (R1507). PLoS One 2009; 4: e7273. 10.1371/journal.pone.0007273
- Cappuzzo F, Tallini G, Finocchiaro G, Wilson RS, Ligorio C, Giordano L, et al. Insulin-like growth factor receptor 1 (IGF1R) expression and survival in surgically resected non-small-cell lung cancer (NSCLC) patients. Ann Oncol 2010; 21: 562-7. 10.1093/annonc/mdp357
- Ning XH, Wang YZ, Bai CM, Li J. Clinical significance of insulin-like growth factor-1 receptor in platinum-based chemotherapy for non-small celllung cancer. [Chinese]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2010; 32: 366-70. 10.3881/j.issn.1000-503X.2010.04.002
- Tsuta K, Mimae T, Nitta H, Yoshida A, Maeshima AM, Asamura H, et al. Insulin-like growth factor-1 receptor protein expression and gene copy number alterations in non-small cell lungcarcinomas. Hum Pathol 2013; 44: 975-82. 10.1016/j.humpath.2012.09.002
- Ludovini V, Flacco A, Bianconi F, Ragusa M, Vannucci J, Bellezza G, et al. Concomitant high gene copy number and protein overexpression of IGF1R and EGFR negatively affect disease-free survival of surgically resected non-small-cell-lung cancer patients. Cancer Chemother Pharmacol 2013; 71: 671-80. 10.1007/s00280-012-2056-y
- Zhang X, Sun J, Wang H, Lou Y, Zhang Y, Sha H, et al. IGF-1R and Bmi-1 expressions in lung adenocarcinoma and their clinicopathologic and prognostic significance. Tumour Biol 2014; 35: 739-45. 10.1007/s13277-013-1100-9
- Gately K, Forde L, Cuffe S, Cummins R, Kay EW, Feuerhake F, et al. High coexpression of both EGFR and IGF1R correlates with poor patient prognosis in resected non-small-cell lung cancer. Clin Lung Cancer 2014; 15: 58-66. 10.1016/j.cllc.2013.08.005
- Tran TN, Selinger CI, Yu B, Ng CC, Kohonen-Corish MR, McCaughan B, et al. Alterations of insulin-like growth factor-1 receptor gene copy number and protein expression are common in non-small cell lung cancer. J Clin Pathol 2014; 67: 985-91. 10.1136/jclinpath-2014-202347
- Nakagawa M, Uramoto H, Shimokawa H, Onitsuka T, Hanagiri T, Tanaka F. Insulin-like growth factor receptor-1 expression predicts postoperative recurrence in adenocarcinoma of the lung. Exp Ther Med 2011; 2: 585-90. 10.3892/etm.2011.258
- Kim JS, Kim ES, Liu D, Lee JJ, Solis L, Behrens C, et al. Prognostic impact of insulin receptor expression on survival of patients with non small cell lung cancer. Cancer 2012; 118: 2454-65. 10.1002/cncr.26492
- Yamamoto T, Oshima T, Yoshihara K, Nishi T, Arai H, Inui K, et al. Clinical significance of immunohistochemical expression of insulin-like growth factor-1 receptor and matrixmetalloproteinase-7 in resected non-small cell lung cancer. Exp Ther Med 2012; 3: 797-802. 10.3892/etm.2012.493
- Xu C, Xie D, Yu SC, Yang XJ, He LR, Yang J, et al. β-Catenin/POU5F1/SOX2 transcription factor complex mediates IGF-I receptor signaling and predicts poor prognosis in lung adenocarcinoma. Cancer Res 2013; 73: 3181-9. 10.1158/0008-5472.CAN-12-4403
- Cappuzzo F, Toschi L, Tallini G, Ceresoli GL, Domenichini I, Bartolini S, et al. Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib. Ann Oncol 2006; 17: 1120-7. 10.1093/annonc/mdl077
- Kikuchi R, Sonobe M, Kobayashi M, Ishikawa M, Kitamura J, Nakayama E, et al. Expression of IGF1R is associated with tumor differentiation and survival in patients with lung adenocarcinoma. Ann Surg Oncol 2012; 19(Suppl 3): S412-20. 10.1245/s10434-011-1878-x.
- Kim YH, Sumiyoshi S, Hashimoto S, Masago K, Togashi Y, Sakamori Y, et al. Expressions of insulin-like growth factor receptor-1 and insulin-like growth factor binding protein 3 in advanced non-small-cell lung cancer. Clin Lung Cancer 2012; 13: 385-90. 10.1016/j.cllc.2011.11.009
- Park E, Park SY, Kim H, Sun PL, Jin Y, Cho SK, et al. Membranous Insulin-like Growth Factor-1 Receptor (IGF1R) Expression Is Predictive of Poor Prognosis in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Lung Adenocarcinoma. J Pathol Transl Med 2015; 49: 382-8. 10.4132/jptm.2015.07.10
- Zhao S, Qiu Z, He J, Li L, Li W. Insulin-like growth factor receptor 1 (IGF1R) expression and survival in non-small cell lung cancer patients: a meta-analysis. IntJ Clin Exp Pathol 2014; 7: 6694-704.
- Richardson LC, Pollack LA. Therapy insight: Influence of type 2 diabetes on the development, treatment and outcomes of cancer. Nat Clin Pract Oncol 2005; 2: 48-53. 10.1038/ncponc0062
- Ding J, Tang J, Chen X, Men HT, Luo WX, Du Y, et al. Expression characteristics of proteins of the insulin-like growth factor axis in non-small cell lung cancer patients with preexisting type 2 diabetes mellitus. Asian Pac J Cancer Prev 2013; 14: 5675-80.
- LeRoith D, Roberts CT Jr. The insulin-like growth factor system and cancer. Cancer Lett 2003; 195: 127-37.
- Wang HS, Wang TH. Polycystic ovary syndrome (PCOS), insulin resistance and insulin-like growth factors (IGfs)/IGF-binding proteins (IGFBPs). Chang Gung Med J 2003; 26: 540-53.
- Zhou Y, Zhang X, Gu C, Xia J. Diabetes mellitus is associated with breast cancer: systematic review, meta-analysis, and in silico reproduction. Panminerva Med 2015; 57: 101-8.
- Jiang Y, Ben Q, Shen H, Lu W, Zhang Y, Zhu J. Diabetes mellitus and incidence and mortality of colorectal cancer: a systematic review and meta-analysis of cohort studies. Eur J Epidemiol 2011; 26: 863-76. 10.1007/s10654-011-9617-y
- Tian T, Zhang LQ, Ma XH, Zhou JN, Shen J. Diabetes mellitus and incidence and mortality of gastric cancer: a meta-analysis. Exp Clin Endocrinol Diabetes 2012; 120: 217-23. 10.1055/s-0031-1297969
- Walter U, Kohlert T, Rahbari NN, Weitz J, Welsch T. Impact of preoperative diabetes on long-term survival after curative resection of pancreatic adenocarcinoma: a systematic review and meta-analysis. Ann Surg Oncol 2014; 21: 1082-9. 10.1245/s10434-013-3415-6
- Wang YG, Wang P, Wang B, Fu ZJ, Zhao WJ, Yan SL. Diabetes mellitus and poorer prognosis in hepatocellular carcinoma: a systematic review and meta-analysis. PLoS One. 2014; 9: e95485. 10.1371/journal.pone.0095485
- Cai H, Xu Z, Xu T, Yu B, Zou Q. Diabetes mellitus is associated with elevated risk of mortality amongst patients with prostate cancer: a meta-analysis of 11 cohort studies. Diabetes Metab Res Rev 2015; 31: 336-43. 10.1002/dmrr.2582
- Chen L, Li H, Gu L, Ma X, Li X, Gao Y, et al. The impact of diabetes mellitus on renal cell carcinoma prognosis: a meta-analysis of cohort studies. Medicine (Baltimore) 2015; 94: e1055. 10.1097/MD.0000000000001055
- Jiamset I, Hanprasertpong J. Impact of diabetes mellitus on oncological outcomes after radical hysterectomy for early stage cervical cancer. J Gynecol Oncol 2016; 27: e28. 10.3802/jgo.2016.27.e28
- Inal A, Kaplan MA, Kucukoner M, Urakci Z, Kilinc F, Isikdogan A. Is diabetes mellitus a negative prognostic factor for the treatment of advanced nonsmall-cell lung cancer? Rev Port Pneumol 2014; 20: 62-8. 10.1016/J.rppneu.2013.09.001
- Hatlen P, Gronberg BH, Langhammer A, Carlsen SM, Amundsen T. Prolonged survival in patients with lung cancer with diabetes mellitus. J Thorac Oncol 2011; 6: 1810-7. 10.1097/JTO.0b013e31822a75be
- Imai H, Kaira K, Mori K, Ono A, Akamatsu H, Matsumoto S, et al. Prognostic significance of diabetes mellitus in locally advanced non-small cell lung cancer. BMC Cancer 2015; 15: 989. 10.1186/s12885-015-2012-4
- Zhu L, Cao H, Zhang T, Shen H, Dong W, Wang L, et al. The effect of diabetes mellitus on lung cancer prognosis: a PRISMA-compliant meta-analysis of cohort studies. Medicine (Baltimore) 2016; 95: e3528. 10.1097/MD.0000000000003528
- Yin M, Zhou J, Gorak EJ, Quddus F. Metformin is associated with survival benefit in cancer patients with concurrent type 2 diabetes: a systematic review and meta-analysis. Oncologist 2013; 18: 1248-55. 10.1634/theoncologist.2013-0111
- Altman DG, McShane LM, Sauerbrei W, Taube SE. Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration. PLoS Med 2012; 9: e1001216. 10.1371/journal.pmed.1001216
Language: English
Page range: 195 - 202
Submitted on: Oct 16, 2016
Accepted on: Nov 8, 2016
Published on: Apr 26, 2017
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
Related subjects:
© 2017 Mojca Humar, Izidor Kern, Gregor Vlacic, Vedran Hadzic, Tanja Cufer, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.